Genentech ( Genentech )

Genentech

Genentech's picture

About Genentech

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.

Genentech press release, blog etc

09/13/2018 - 18:58 FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis
09/04/2018 - 23:58 Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer (WCLC)
08/29/2018 - 11:38 Positive Phase III Results for Genentechs HEMLIBRA (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine
08/12/2018 - 10:07 FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies
07/25/2018 - 11:45 Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
07/19/2018 - 05:27 Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimers Program at the Upcoming Alzheimer's Association International Conference (AAIC)
07/18/2018 - 07:56 Genentechs TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People With Advanced Lung Cancer
07/17/2018 - 18:05 FDA Grants Breakthrough Therapy Designation for Genentechs TECENTRIQ in Combination With Avastin as First-Line Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)
07/11/2018 - 03:01 Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy
07/01/2018 - 17:24 Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
06/25/2018 - 19:36 FDA Grants Priority Review to Genentechs Baloxavir Marboxil for the Treatment of Influenza
06/24/2018 - 18:21 Genentechs TECENTRIQ in Combination with Chemotherapy Helped People with Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy
06/13/2018 - 12:03 FDA Approves Genentechs Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
06/13/2018 - 11:06 Genentech Announces New Ocrevus (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of two Global Studies in Progressive MS
06/08/2018 - 11:19 Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
06/07/2018 - 08:36 FDA Approves Genentechs Rituxan (Rituximab) for Pemphigus Vulgaris
06/04/2018 - 05:29 FDA Grants Priority Review to Genentechs HEMLIBRA (emicizumab-kxwh) for People With Hemophilia A Without Factor VIII Inhibitors
06/02/2018 - 12:17 Phase III IMpower131 Study Showed Genentechs TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced the Risk of Disease Worsening or Death for People With Advanced Squamous Non-Small Cell Lung Cancer